Park Medi World (PARKHOSPS)

FairStock Score: 31/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 17.76% with ROCE of 20.36% indicates efficient capital deployment
• Piotroski F-score of 7/9 suggests decent financial health
• Promoter holding of 82.89% aligns management interests with minority shareholders
• Debt/Equity of 0.58 shows a manageable balance sheet
• Latest quarter sales of ₹410 crore and net profit of ₹53 crore demonstrate operating scale

Concerns

• P/E of 39.39 and PEG of 2.70 are expensive relative to 11.38% profit growth
• Profit growth trails sales growth, indicating possible margin pressure
• Zero dividend means minority investors rely entirely on price appreciation
• P/B of 7.31 against book value of ₹31.24 leaves no asset-based margin of safety

AI Analysis

Park Medi World has a set of numbers that initially appeal to me. Sales are growing at 17.76%, ROCE is a healthy 20.36%, and debt/equity is only 0.58. Add a Piotroski F-score of 7/9 and promoter holding of 82.89%, and there are signs of a well-run hospital business. A 20% return on capital hints at competitive strength, though I cannot confirm a durable moat from these figures alone. But valuation is where my enthusiasm stops. At ₹228.35, I am paying ₹8,339 crore for the company, or 39.39 times trailing earnings and 7.31 times book value. Book value is just ₹31.24. This leaves little margin of safety. Profit growth is only 11.38%, so the PEG ratio of 2.70 tells me I am paying far too much for the growth available. My earnings yield is roughly 2.5%, well below what I would demand from an investment in a risky equity. The latest quarter does show decent operating performance — sales of ₹410 crore and net profit of ₹53 crore — but profit growth has not kept pace with sales growth. That suggests margin pressure, not pricing power expansion. There is no dividend, so the minority holder must depend entirely on future price appreciation. ROE is not available, which bothers me; I want to see earnings generated on equity, not simply a high price-to-book multiple. Graham taught me to be most cautious when the story looks good and the price looks better. Here, the price looks speculative. I would wait for either a meaningful pullback or proof that profit growth can accelerate to match sales growth. Until then, Park Medi World is a good business at a demanding price — worth watching, not buying.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer